Navigation Links
TissueGene Announces Regulatory Allowance to Initiate Phase IIa Study of TG-C in South Korea for Osteoarthritis of the Knee
Date:3/2/2009

ROCKVILLE, Md., March 2 /PRNewswire/ -- TissueGene, Inc. announced today that its South Korean licensing partner Kolon Life Science, Inc. (KLS) has received regulatory allowance from the Korea Food and Drug Administration (KFDA) to initiate a Phase IIa clinical trial of TissueGene-C (TG-C) in patients with severe osteoarthritis of the knee. TG-C has been developed for the localized delivery of allogeneic human cells expressing TGF-beta1 in order to induce the regeneration of cartilage.

In Asia, TissueGene has licensed intellectual property rights to KLS, a subsidiary of Kolon, for the clinical development and commercialization of TissueGene's lead product candidates TG-C and TG-B, developed for the regeneration of cartilage and bone, respectively. Under the terms of the agreement, TissueGene has received an undisclosed up-front payment and will receive on-going royalty payments based upon future sales. TissueGene is currently completing Phase I clinical trials in the U.S. and continues to work closely with KLS in order to coordinate their regulatory efforts and efficiently conduct parallel clinical trials for TG-C in both the U.S. and Korea.

The Phase IIa clinical trial is designed as a randomized, multi-center study in order to evaluate the safety and efficacy of TG-C in patients with Grade IV Degenerative Joint Disease (DJD) of the knee, who have been unresponsive to existing therapies. The patients will receive an intra-articular injection to the damaged joint area at one of two dose levels of TG-C. The primary endpoint of the trial will be evidence of symptomatic improvement and the secondary endpoint will be evidence of cartilage regeneration through MRI evaluation.

"The launch of this Phase II study represents a critical step in the development of a commercially and clinically viable mechanism to initiate regeneration of cartilage for patients suffering from osteoarthritis," stated Dr. Kwan Hee L
'/>"/>

SOURCE TissueGene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Pharmaxis Announces New Drug Application Submission for Aridol(TM)
2. Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
3. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
4. Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects
5. Impact Medical Solutions Announces Initiation of Pilot Clinical Trial and Listing on Frankfurt Stock Exchange
6. Bone Biologics Announces Significant Milestone for Spinal Fusion Surgery Using Recombinant Protein and Demineralized Bone Matrix
7. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
8. Kensey Nash Announces IDE Submission for Cartilage Repair Device
9. MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
10. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
11. Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013 Decision ... advisory firms for pharmaceutical and healthcare issues, finds ... therapies offering a greater effect on quality of ... need. Given the high level of subjectivity and ... life, interviewed thought leaders state that it is ...
(Date:5/19/2013)...  Whole-cell pertussis vaccines were more effective at protecting ... recent outbreak, according to a new Kaiser Permanente study ... called DTwP, were available from the 1940s to 1990s, ... to the development of acellular pertussis vaccines, which are ... the United States had switched from whole-cell ...
(Date:5/18/2013)... FRANCISCO , May 18, 2013 ... MadinAmerica.com , Occupy Psychiatry , ... mental health care, announces a social media campaign ... the traditional psychiatric model, which focuses on pathology ... launch coincides with the American Psychiatric Association,s (APA) ...
Breaking Medicine Technology:For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3
... RA Signs and Symptoms Compared to Placebo, ... (Nasdaq: TRBN ) today announced preliminary ... double-blind, placebo-controlled, multicenter,clinical trial of its TRU-015 ... indicated that Trubion,s TRU-015 product candidate, at,well-tolerated ...
... Calif., Sept. 10 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... antibodies for the treatment of cancer and,hepatitis C ... submitted a,clinical protocol with the Drug Controller General ... safety and efficacy trial of bavituximab in combination,with ...
Cached Medicine Technology:Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 2Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 3Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 4Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 5Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 2Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 3Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 4
(Date:5/21/2013)... May 21, 2013 The birth control ... women who have used the contraceptive NuvaRing. A new ... blood clot injuries has increased in recent months*. , ... drugs and devices with the latest safety alerts, recalls, ... others are experiencing similar side effects and decide if ...
(Date:5/20/2013)... CA (PRWEB) May 21, 2013 USA ... A Transcendent Approach to Peak Performance" won the top ... Non-Fiction Category. Chosen over a multitude of international ... global attention and critical acclaim from both mainstream and ... levels - mentally, physically and spiritually. , ...
(Date:5/20/2013)... 21, 2013 The automated external ... into two categories - semi-automated and fully automated ... into five categories, namely, hospitals, pre-hospital, public access, ... till 2017. Automated external defibrillators play an important ... arrest victims. Considering the life-saving potential of AEDs, ...
(Date:5/20/2013)... Los Angeles, CA (PRWEB) May 20, 2013 ... light on the importance of using green and ... Canadian federal government has implemented regulations to promote ... for the Packaging and Labelling Services industry ... also supported this trend,” says IBISWorld industry analyst ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 In order to ... health and wellness team from DrSmartphoneMD launched an article series ... sunburns. , The series launched with the precautions ... members of the DrSmartphoneMD program are not one of the ... explained that more than 90% of all skin cancer cases ...
Breaking Medicine News(10 mins):Health News:DrugRisk Update Shows Increase in NuvaRing Blood Clot Lawsuits 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 3Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 2Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 3Health News:Packaging and Labelling Services in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Packaging and Labelling Services in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Combat Skin Cancer In Summer Months 2
... ... mental health illness stereotypes , ... Arlington, VA (PRWEB) October 28, 2009 -- As Halloween approaches, the ... alert" for costumes and other seasonal attractions that feature inaccurate and offensive stereotypes ...
... DENVER, Oct. 28 Many medical practices are struggling. ... making basic business mistakes, according to Andrew Graham, MBA, ... top reasons practices struggle, said Graham. , ... to include goals for revenue generation, customer service, performance ...
... 28 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA ... commercialization of clinical-stage product candidates for central nervous system ... quarter ended September 30, 2009, on Monday, November 2, ... of the release will be disseminated at that time. ...
... Oct. 28 The cutting-edge of assistive technology--including ... showcased at the Assistive Technology Pavilion at Abilities ... 6-8, 2009 at the Cobb Galleria Convention Center. ... caregivers and healthcare professionals are expected to attend ...
... 28 What happens when intended parents cross international borders ... of Mumbai, India-based law firm Menon & Associates ( ... Family Solutions was among the panel speakers on ... Association Section of Family Law recently held in Montreal, Canada. ...
... , NASDAQ: CRME ... /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) and its ... patient enrolment has begun for the ACT 5 trial, a ... a drug product candidate under development for the rapid conversion ...
Cached Medicine News:Health News:NAMI Issues "Stigma Alert" Over Inaccurate and Offensive Halloween Costumes, Attractions 2Health News:NAMI Issues "Stigma Alert" Over Inaccurate and Offensive Halloween Costumes, Attractions 3Health News:The Top 10 Business Mistakes Made By Physician Practices 2Health News:Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009 2Health News:Experience the Future of Assistive Technology at Abilities Expo on November 6-8, 2009 2Health News:Legislation in India to Address Assisted Reproductive Technology, Egg Donation and Surrogacy 2Health News:Cardiome And Astellas Announce Initiation Of Patient Enrolment In ACT 5 Trial 2Health News:Cardiome And Astellas Announce Initiation Of Patient Enrolment In ACT 5 Trial 3Health News:Cardiome And Astellas Announce Initiation Of Patient Enrolment In ACT 5 Trial 4
Anorectal Stylet for LATITUDE® Air-Charged Catheter...
Omnilink Adapter Cable for LATITUDE® Air-Charged Catheter...
Solid State Manometry Catheter Accessory., ,Manometric calibrators are required for calibration of solid state catheters., ,Each type of catheter requires a unique calibrator....
... The ITREL 3 is a battery ... in the U.S., ,Enterra™ Therapy is ... and vomiting associated with gastroparesis when conventional ... of symptons for diabetic or idiopathic patients., ...
Medicine Products: